A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2

Cancer Research

Volumn 63, Issue 14, 2003, Pages 4062-4066

  Mansour, Ahmed M ^a,c   Drevs, Joachim ^a   Esser, Norbert ^a   Hamada, Farid M ^c   Badary, Osama A ^c   Unger, Clemens ^a   Fichtner, Iduna ^b   Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c Al Azhar University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DOXORUBICIN; GELATINASE A; MALEIMIDE DERIVATIVE; PRODRUG;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

ALBUMINS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; HUMANS; MALEIMIDES; MATRIX METALLOPROTEINASE 2; MELANOMA; OLIGOPEPTIDES; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 0042173127     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sun, W., and Schuchter, L. M. Metastatic melanoma. Curr. Treat. Options Oncol., 2: 193-202, 2001.
2. Stetler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol., 9: 541-573, 1993.
3. de Vries, T. J., van Muijen, G. N., and Ruiter, D. J. The plasminogen activation system in melanoma cell lines and in melanocytic lesions. Melanoma Res., 6: 79-88, 1996.
4. Chambers, A. F., and Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst., 89: 1260-1270, 1997.
5. Curran, S., and Murray, G. I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol., 189: 300-308, 1999.
6. Hofmann, U. B., Westphal, J. R., van Muijen, G. N. P., and Ruiter, D. J. Matrix metalloproteinases in human melanoma. J. Investig. Dermatol. 115: 337-344, 2000.
7. Hofmann, U. B., Westphal, J. R., Waas, E. T., Zendman, A. J. W., Cornelissen, I. M. H. A., Ruiter, D. J., and van Muijen, G. N. P. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br. J. Cancer, 81: 774-782, 1999.
8. Kurschat, P., Zigrino, P., Nischt, R., Breitkopf, K., Steurer, P., Klein, C. E., Krieg, T., and Mauch, C. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J. Biol. Chem., 274: 21056-21062, 1999.
9. Väisänen, A., Tuominen, H., Kallioinen, M., and Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J. Pathol., 180: 283-289, 1996.
10. Fiebig, H. H., Klostermeyer, A., Schüle, J. B., and Burger, A. Characterization of matrix metalloproteinases in 47 human tumor xenografts show high expression of MMP-2 in melanomas and sarcomas. Proc. Am. Assoc. Cancer Res., 40: 463, 1999.
11. Kratz, F., Drevs, J., Bing, G., Stockmar, C., Scheuermann, K., Lazar, P., and Unger, C. Development and in vitro efficacy of novel MMP-2 and MMP-9 specific doxorubicin albumin conjugates. Bioor. Med. Chem. Lett., 11: 2001-2006, 2001.
12. Kratz, F., Müller-Driver, R., Hofmann, I., Drevs, J., and Unger, C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem., 43: 1253-1256, 2000.
13. Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Drückes, P., Esser, N., Drevs, J., Rognan, D., Bissantz, C., Hinderling, C., Folkers, G., Fichtner, I., and Unger, C. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive Doxorubicin derivative with specific albumin-binding properties compared with the parent compound. J. Med. Chem., 45: 5523-5533, 2002.
14. Cole, S. P. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother. Pharmacol., 17: 259-263, 1986.
15. Loadman, P. M., Bibby, M. C., Double, J. A., Al-Shakhaa, W. M., and Duncan, R. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin. Cancer Res., 5: 3682-3688, 1999.
16. Murdter, T. E., Sperker, B., Kivisto, K. T., McClellan, M., Fritz, P., Friedel, G., Linder, A., Bosslet, K., Toomes, H., Dierkesmann, R., and Kroemer, H. K. Enhanced uptake of doxorubicin into bronchial carcinoma: β-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res., 57: 2440-2445, 1997.
17. Denmeade, S. R., Nagy, A., Gao, J., Lilja, H., Schally, A. V., and Isaacs, J. T. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res., 58: 2537-2540, 1998.
18. DeFeo-Jones, D., Garsky, V. M., Wong, B. K., Feng, D. M., Bolyar, T., Haskell, K., Kiefer, D. M., Leander, K., McAvoy, E., Lumma, P., Wai, J., Senderak, E. T., Motzel, S. L., Keenan, K., Van Zwieten, M., Lin, J. H., Freidinger, R., Huff, J., Oliff, A., and Jones, R. E., A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med., 6: 1248-1252, 2000.
19. Dubois, V., Dasnois, L., Lebtahi, K., Collot, F., Heylen, N., Havaux, N., Fernandez, A. M., Lobl, T. J., Oliyai, C., Nieder, M., Shochat, D., Yarranton, G. T., and Trouet, A. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity. Cancer Res., 62: 2327-2331, 2002.
20. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release, 65: 271-284, 2000.